Search Nonprofits

Your support makes it possible for us to offer high-quality patient education from top scleroderma experts, facilitate patient support groups and fund promising research.

Our mission is to find a effective treatments and ultimately a cure for fragile X syndrome, the most common inherited cause of autism. We directly fund research grants and fellowships at top universities around the world. FRAXA was founded in 1994 by three parents of children with fragile X. Fragile X Syndrome is the most common inherited cause of autism and intellectual disabilities. It affects 1 in 4000 boys and 1 in 6000 girls worldwide, and one in 260 women and 1 in 800 men are carriers. Treatments for fragile X are likely to help people affected by related disorders including autism, Alzheimers, and many other brain disorders.

THE HOSPICE OF DAYTON, INC. IS COMMITTED TO MAKING QUALITY HOSPICE CARE AVAILABLE AND ACCESSIBLE TO TERMINALLY ILL PERSONS AND THEIR FAMILIES, REGARDLESS OF ABILITY TO PAY, AND IN A MANNER CONSISTENT WITH THE HIGHEST HOSPICE STANDARDS. OUR COMMITMENT TO THE HOSPICE PHILOSOPHY OF CARE INCLUDES A COMPASSIONATE STAFF PLEDGED TO CONTINUOUSLY IMPROVE AND ENHANCE THE CARE WE PROVIDE, RESPECT THE PATIENTS' CHOICES OF CARE, RESPOND TO CHANGING COMMUNITY NEEDS, AND SERVE AS A RESOURCE TO OTHERS FOR IMPROVING THE AVAILABILITY OF QUALITY HOSPICE CARE.

The Lymphoma Research Foundation's mission is to eradicate lymphoma and serve those touched by this disease.

The Huntington's Disease Society of America is the premier nonprofit organization dedicated to improving the lives of everyone affected by Huntington’s disease. From community services and education to advocacy and research, HDSA is the world’s leader in providing help for today and hope for tomorrow for people with Huntington’s disease and their families. HDSA's network of chapters, affiliates, HDSA Centers of Excellence, social workers and support groups provides a seamless connection for help, education and outreach to HD families and health care professionals across the United States.

Clearbrook is committed to being a leader in creating innovative opportunities, services and supports for people with disabilities. We serve people over a range of ages and disabilities from children diagnosed with developmental delays at birth to the unique needs of seniors with disabilities and all ages in between. Annually, we support over 8,000 individuals as well as their families in 15 counties, in over 160 communities and 50 locations throughout Chicago, the suburbs, and northern Illinois. We are proud to be the largest provider of home-based services in Illinois.

The Foundation Fighting Blindness, Inc. is the world’s leader in providing awareness and funding that drives the research that will provide preventions, treatments and cures for people affected by retinal degenerative diseases.

Our mission is to advance the awareness and treatment of Angelman Syndrome through education and information, research, advocacy, and support for individuals with Angelman Syndrome, their families, and other concerned parties.

Our Mission: To partner with the ALS community as we drive the discovery of prevention strategies, treatments, and cures for ALS; provide access to quality care and connection; and promote initiatives to improve health outcomes.

Little City is dedicated to serving children and adults with intellectual and developmental disabilities by providing the best options and opportunities to live safely, learn continuously, explore creatively and work productively throughout their lifetime. By inspiring, advocating and pursuing success with passion and purpose, lives are changed through hope, happiness, and optimism.

Mission: To facilitate global collaboration and fund world-class research, medical education, and treatment trials, that make a positive impact on the lives of people with ME/CFS, Long COVID and related diseases. Vision: Significantly improve patient outcomes while advancing a cure. Goals: Our primary goals are to: frame clear disease mechanisms and models; find effective treatments and diagnostic markers; increase accurate diagnoses; and ensure access to quality care.

The mission of the NOCC is to save lives through the prevention and cure of ovarian cancer and to improve quality of life for survivors and their caregivers. Nearly 19,800+ women in the United States are diagnosed with ovarian cancer each year, and approximately 12,800+ women die from the disease. Unfortunately, most cases are diagnosed in later stages when the prognosis is poor. However, if diagnosed and treated early when the cancer is confined to the ovary, the five-year survival rate is over 90 percent. This is why it’s imperative that the early signs and symptoms are recognized not only by women, but by their families and the healthcare community.